MedWatch

Ascendis Pharma aims to raise USD 112 million

Danish biotech company Ascendis Pharma has announced a public offering of ADSs in a bid to raise up to USD 112 million.

Photo: Colourbox

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

Nævn afviser tilskud til Novos fedmemiddel

Prisen for fedmemidlet Saxenda fra Novo Nordisk står ikke mål med effekten, mener Lægemiddelstyrelsens Medicintilskudsnævn, der har indstillet til, at danske patienter ikke skal have tilskud til behandling med midlet uden en særlig god forklaring.

Related articles